About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Braf
Braf transforming gene
MGI:88190
235 phenotypes from 19 alleles in 35 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Braftm1(ARAF)Urr/Braftm1(ARAF)Urr
involves: 129S1/Sv * C57BL/6
embryonic lethality during organogenesis, incomplete penetrance J:112971
increased apoptosis J:112971
Braftm1(ARAF)Urr/Braftm1(ARAF)Urr
involves: 129S1/Sv * C57BL/6 * CD-1
abnormal cerebral cortex pyramidal cell morphology J:112971
abnormal somatosensory cortex morphology J:112971
abnormal stratification in cerebral cortex J:112971
abnormal telencephalon development J:112971
abnormal visual cortex morphology J:112971
decreased body weight J:112971
decreased embryo size J:112971
decreased spleen weight J:112971
decreased thymus weight J:112971
embryonic lethality during organogenesis, incomplete penetrance J:112971
premature death J:112971
thin cerebral cortex J:112971
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL
abnormal crypts of Lieberkuhn morphology J:199307
abnormal intestinal epithelium morphology J:199307
abnormal intestinal mucosa morphology J:199307
abnormal large intestine crypts of Lieberkuhn morphology J:199307
abnormal large intestine morphology J:199307
abnormal small intestinal villus morphology J:199307
abnormal small intestine morphology J:199307
branched small intestinal villi J:199307
increased carcinoma incidence J:199307
increased gastrointestinal tumor incidence J:199307
increased intestinal adenoma incidence J:199307
increased large intestine length J:199307
increased small intestine length J:199307
intestine polyps J:199307
Braftm1.1Eyc/Braftm1.1Eyc
either: (involves: 129S2/SvPas * FVB/N ) or (involves: 129S2/SvPas * BALB/c * C57BL/6)
normal behavior/neurological phenotype J:168330
Braftm1.1Sva/Braftm1.1Sva
involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ
abnormal placenta labyrinth morphology J:105998
abnormal placenta morphology J:105998
abnormal placental labyrinth vasculature morphology J:105998
abnormal spongiotrophoblast layer morphology J:105998
abnormal trophoblast layer morphology J:105998
decreased embryo size J:105998
embryonic lethality during organogenesis, complete penetrance J:105998
Braftm1.1Sva/Braftm1.1Sva
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
embryonic growth retardation J:121660
embryonic lethality during organogenesis, complete penetrance J:121660
increased neuron apoptosis J:121660
Braftm1.1Wds/Braftm1.1Wds
involves: 129P2/OlaHsd * C57BL/6
embryonic growth retardation J:121660
embryonic lethality during organogenesis, complete penetrance J:121660
increased neuron apoptosis J:121660
Braftm1Bbd/Braf+
B6.129-Braftm1Bbd
abnormal basicranium morphology J:170095
abnormal cell morphology J:170095
abnormal frontal bone morphology J:170095
abnormal immune system physiology J:170095
abnormal kidney morphology J:170095
abnormal mating frequency J:170095
abnormal neurocranium morphology J:170095
abnormal pancreatic acinar cell morphology J:170095
abnormal parietal bone morphology J:170095
abnormal skin sebaceous gland morphology J:170095
abnormal thymus morphology J:170095
cataract J:170095
decreased body size J:170095
decreased body weight J:170095
decreased creatinine clearance J:170095
decreased thymocyte number J:170095
decreased white adipose tissue amount J:170095
enlarged heart J:170095
hyperactivity J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
oliguria J:170095
premature death J:170095
round head J:170095
shortened head J:170095
thymus atrophy J:170095
Braftm1Bbd/Braf+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
abnormal basicranium morphology J:170095
abnormal cell morphology J:170095
abnormal frontal bone morphology J:170095
abnormal immune system physiology J:170095
abnormal kidney morphology J:170095
abnormal mating frequency J:170095
abnormal neurocranium morphology J:170095
abnormal pancreatic acinar cell morphology J:170095
abnormal parietal bone morphology J:170095
abnormal skin sebaceous gland morphology J:170095
abnormal thymus morphology J:170095
cataract J:170095
decreased body size J:170095
decreased body weight J:170095
decreased thymocyte number J:170095
decreased white adipose tissue amount J:170095
enlarged heart J:170095
hyperactivity J:170095
increased circulating noradrenaline level J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
postnatal lethality, incomplete penetrance J:170095
premature death J:170095
round head J:170095
shortened head J:170095
thymus atrophy J:170095
Braftm1Bbd/Braf+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1
abnormal astrocyte morphology J:170095
abnormal basicranium morphology J:170095
abnormal cell morphology J:170095
abnormal dermal melanocyte morphology J:170095
abnormal frontal bone morphology J:170095
abnormal immune system physiology J:170095
abnormal kidney morphology J:170095
abnormal mating frequency J:170095
abnormal neurocranium morphology J:170095
abnormal pancreatic acinar cell morphology J:170095
abnormal parietal bone morphology J:170095
abnormal skin sebaceous gland morphology J:170095
abnormal thymus morphology J:170095
cataract J:170095
convulsive seizures J:170095
decreased body size J:170095
decreased body weight J:170095
decreased thymocyte number J:170095
decreased white adipose tissue amount J:170095
enlarged heart J:170095
heart hyperplasia J:170095
hyperactivity J:170095
increased cardiac muscle contractility J:170095
increased gland tumor incidence J:170095
increased lung adenoma incidence J:170095
increased metastatic potential J:170095
increased pheochromocytoma incidence J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
premature death J:170095
round head J:170095
shortened head J:170095
tachypnea J:170095
thymus atrophy J:170095
Braftm1Cpri/Braf+
involves: 129P2/OlaHsd
increased cell proliferation J:187371
increased lung adenoma incidence J:187371
increased lung tumor incidence J:187371
Braftm1Cpri/Braf+
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
abnormal liver morphology J:104375
decreased bone marrow cell number J:104375
decreased erythrocyte cell number J:104375
decreased leukocyte cell number J:104375
enlarged spleen J:104375
extramedullary hematopoiesis J:104375
increased leukemia incidence J:104375
premature death J:104375
Braftm1Cpri/Braf+
Tg(CMV-cre)1Cgn/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
embryonic lethality between implantation and somite formation, complete penetrance J:104375
Braftm1Cpri/Braf+
Scn10atm2(cre)Jnw/Scn10a+
involves: 129 * 129P2/OlaHsd
abnormal dorsal root ganglion morphology J:205122
abnormal innervation J:205122
abnormal nervous system electrophysiology J:205122
abnormal neuron physiology J:205122
normal behavior/neurological phenotype J:205122
enhanced behavioral response to xenobiotic J:205122
excessive scratching J:205122
skin lesions J:205122
Braftm1Cpri/Braftm1Cpri
involves: 129P2/OlaHsd * C57BL/6
increased fibroblast proliferation J:104375
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0
involves: 129P2/OlaHsd * FVB/NCr
decreased activity of thyroid J:168249
decreased body weight J:168249
increased circulating thyroid-stimulating hormone level J:168249
increased circulating thyroxine level J:168249
increased thyroid carcinoma incidence J:168249
increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
hyperpigmentation J:147434
increased melanoma incidence J:147434
increased skin tumor incidence J:147434
spontaneous skin ulceration J:147434
Braftm1Mmcm/Braf+
involves: 129P2/OlaHsd
increased lung adenocarcinoma incidence J:121715
increased lung adenoma incidence J:121715
increased lung tumor incidence J:121715
lung epithelium hyperplasia J:121715
premature death J:121715
Braftm1Mmcm/Braf+
involves: 129P2/OlaHsd
no abnormal phenotype detected J:121715
Braftm1Mmcm/Braf+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * FVB
abnormal melanocyte morphology J:151023
skin lesions J:151023
Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129P2/OlaHsd * C57BL/6 * SJL
increased lung adenoma incidence J:121715
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
increased thyroid carcinoma incidence J:208854
respiratory failure J:208854
Braftm1Mmcm/Braf+
Tg(Tg-cre/ERT2)#Mmcm/0
involves: 129P2/OlaHsd
abnormal thyroid follicle morphology J:172205
abnormal thyroid gland morphology J:172205
decreased activity of thyroid J:172205
decreased circulating thyroxine level J:172205
enlarged thyroid gland J:172205
increased circulating thyroid-stimulating hormone level J:172205
increased thyroid carcinoma incidence J:172205
Braftm1Mmcm/Braftm1Mmcm
Cd207tm2.1(cre)Bjec/Cd207+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
increased dendritic cell number J:211690
liver inflammation J:211690
lung inflammation J:211690
Braftm1Mmcm/Braftm1Mmcm
Tg(Itgax-cre)1-1Reiz/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
abnormal chemokine level J:211690
abnormal cytokine level J:211690
anemia J:211690
enlarged liver J:211690
enlarged lymph nodes J:211690
enlarged spleen J:211690
granulomatous inflammation J:211690
increased dendritic cell number J:211690
increased inflammatory response J:211690
premature death J:211690
Braftm1Mmcm/Braftm1Mmcm
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * FVB
abnormal melanocyte morphology J:151023
Braftm1Mmcm/?
Tg(TPO-cre)1Shk/0
involves: 129P2/OlaHsd * FVB/NCr
decreased birth weight J:172205
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2
normal neoplasm J:161180
normal pigmentation phenotype J:161180
Braftm1Sva/Braftm1.1Sva
Meox2tm1(cre)Sor/Meox2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
lethality at weaning, complete penetrance J:105998
postnatal growth retardation J:105998
Braftm1Sva/Braftm1.1Sva
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
abnormal adenohypophysis morphology J:121660
abnormal body temperature homeostasis J:121660
abnormal growth hormone level J:121660
normal behavior/neurological phenotype J:121660
decreased body weight J:121660
hyperactivity J:121660
hypoglycemia J:121660
lethality at weaning, incomplete penetrance J:121660
normal nervous system phenotype J:121660
postnatal growth retardation J:121660
small adenohypophysis J:121660
thin cerebral cortex J:121660
Braftm1Sva/Braftm1Sva
Tg(Camk2a-cre)1557Sva/0
involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ * FVB
abnormal associative learning J:107042
abnormal spatial learning J:107042
reduced long term potentiation J:107042
Braftm1Sva/Braftm1Sva
Tg(Tek-cre/ERT2)1Arnd/0
involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ
no abnormal phenotype detected J:105998
Braftm1Tumg/Braf+
Tg(CAG-cre)2Osb/0
involves: BALB/c * C57BL * C57BL/6J * DBA
enlarged heart J:226977
female infertility J:226977
hepatic necrosis J:226977
ostium secundum atrial septal defect J:226977
patent cardiac foramen ovale J:226977
postnatal growth retardation J:226977
postnatal lethality, incomplete penetrance J:226977
premature death J:226977
ruffled hair J:226977
sparse hair J:226977
Braftm1Tumg/Braf+
Tg(CAG-cre)2Osb/0
involves: C57BL * C57BL/6J * DBA
abnormal atrioventricular cushion morphology J:216228
abnormal coronary artery morphology J:216228
abnormal epicardium morphology J:216228
abnormal heart development J:216228
abnormal heart morphology J:216228
abnormal lymph organ development J:216228
abnormal myocardial trabeculae morphology J:216228
abnormal pulmonary valve cusp morphology J:216228
cyanosis J:216228
decreased liver weight J:216228
edema J:216228
enlarged heart J:216228
enlarged mitral valve J:216228
enlarged pulmonary valve J:216228
enlarged tricuspid valve J:216228
hemorrhage J:216228
hepatic necrosis J:216228
kyphosis J:216228
lethality throughout fetal growth and development, incomplete penetrance J:216228
mandible hypoplasia J:216228
neonatal lethality, complete penetrance J:216228
pulmonary alveolar hemorrhage J:216228
small liver J:216228
thick pulmonary valve J:216228
thick tricuspid valve J:216228
thin myocardium compact layer J:216228
ventricular septal defect J:216228
Braftm1Tumg/Braf+
Tg(CAG-cre)2Osb/0
involves: C57BL * C57BL/6J * DBA * ICR
abnormal locomotor behavior J:226977
abnormal myocardial fiber morphology J:226977
abnormal myocardial trabeculae morphology J:226977
atrial septal defect J:226977
decreased cranium length J:226977
decreased food intake J:226977
decreased vertical activity J:226977
female infertility J:226977
impaired contextual conditioning behavior J:226977
increased heart weight J:226977
kyphosis J:226977
long nails J:226977
nail dystrophy J:226977
ovary cysts J:226977
polydactyly J:226977
postnatal lethality, incomplete penetrance J:226977
pulmonary valve stenosis J:226977
round head J:226977
ruffled hair J:226977
slow postnatal weight gain J:226977
sparse hair J:226977
thick mitral valve cusps J:226977
thick pulmonary valve cusps J:226977
Braftm1Tumg/Braftm1Tumg
Tg(CAG-cre)2Osb/0
involves: C57BL * C57BL/6J * DBA * ICR
postnatal lethality, complete penetrance J:226977
Braftm1Wds/Braftm1.1Wds
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
abnormal adenohypophysis morphology J:121660
abnormal body temperature homeostasis J:121660
abnormal growth hormone level J:121660
normal behavior/neurological phenotype J:121660
decreased body weight J:121660
hyperactivity J:121660
hypoglycemia J:121660
lethality at weaning, incomplete penetrance J:121660
normal nervous system phenotype J:121660
postnatal growth retardation J:121660
small adenohypophysis J:121660
thin cerebral cortex J:121660
Braftm1Zim/Braftm1Zim
involves: 129/Sv
abnormal aorta morphology J:41257
abnormal apoptosis J:41257
abnormal blood vessel morphology J:41257
abnormal cardinal vein morphology J:41257
abnormal head morphology J:41257
abnormal neuron morphology J:41257
abnormal vascular endothelial cell morphology J:41257
abnormal vitelline vasculature morphology J:41257
decreased embryo weight J:41257
decreased heart rate J:41257
embryonic lethality during organogenesis, complete penetrance J:41257
hematoma J:41257
hemopericardium J:41257
hemorrhage J:41257
increased vascular endothelial cell number J:41257
intraventricular hemorrhage J:41257
poor circulation J:41257
Braftm1Zim/Braftm1Zim
involves: 129/Sv * C57BL/6 * CD-1
abnormal telencephalon development J:112971
embryonic lethality during organogenesis, complete penetrance J:112971
Braftm2.1Eyc/Braftm2.1Eyc
either: (involves: 129S2/SvPas * FVB/N ) or (involves: 129S2/SvPas * BALB/c * C57BL/6)
abnormal long term object recognition memory J:168330
normal behavior/neurological phenotype J:168330
Braftm2.1Urr/Braftm2.1Urr
involves: 129 * C57BL/6 * FVB/N
no abnormal phenotype detected J:199842
Braftm2.1Urr/Braftm2.1Urr
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
abnormal cerebellar molecular layer J:199842
abnormal cerebellum morphology J:199842
abnormal cerebellum vermis lobule I morphology J:199842
abnormal cerebellum vermis lobule II morphology J:199842
abnormal cerebellum vermis lobule III morphology J:199842
abnormal cerebellum vermis lobule morphology J:199842
abnormal cerebellum vermis lobule V morphology J:199842
abnormal cerebellum vermis lobule VII morphology J:199842
abnormal cerebellum vermis lobule X morphology J:199842
abnormal hippocampus granule cell layer J:199842
abnormal Purkinje cell dendrite morphology J:199842
abnormal Purkinje cell morphology J:199842
cerebellum hypoplasia J:199842
decreased body size J:199842
decreased body weight J:199842
decreased brain weight J:199842
decreased Purkinje cell number J:199842
impaired balance J:199842
impaired coordination J:199842
impaired neuron differentiation J:199842
increased aggression J:199842
increased neuronal precursor proliferation J:199842
postnatal lethality, incomplete penetrance J:199842
premature death J:199842
Braftm2.2Urr/Braftm2.2Urr
involves: 129 * C57BL/6 * FVB/N
decreased embryo size J:199842
embryonic growth retardation J:199842
embryonic lethality during organogenesis, complete penetrance J:199842
small placenta J:199842
Braftm2Cpri/Braf+
involves: C57BL/6
normal cellular phenotype J:187371
normal respiratory system phenotype J:187371
Braftm2Cpri/Braf+
Tg(CMV-cre)1Cgn/0
B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn
abnormal eye morphology J:187371
abnormal facial morphology J:187371
abnormal myometrium morphology J:187371
cardiac hypertrophy J:187371
cataract J:187371
decreased body height J:187371
decreased body weight J:187371
enlarged heart J:187371
enlarged myocardial fiber J:187371
enlarged spleen J:187371
increased intestinal adenoma incidence J:187371
increased skin papilloma incidence J:187371
increased spleen weight J:187371
increased susceptibility to ischemic brain injury J:187371
intestine polyps J:187371
long incisors J:187371
lymphoid hyperplasia J:187371
premature death J:187371
thick interventricular septum J:187371
thick ventricular wall J:187371
uterus prolapse J:187371
Braftm2Urr/Braftm2Urr
involves: 129 * C57BL/6
no abnormal phenotype detected J:199842
Braftm2Urr/Braftm2Urr
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
abnormal cerebellar molecular layer J:199842
abnormal cerebellum morphology J:199842
abnormal cerebellum vermis lobule I morphology J:199842
abnormal cerebellum vermis lobule II morphology J:199842
abnormal cerebellum vermis lobule III morphology J:199842
abnormal cerebellum vermis lobule morphology J:199842
abnormal cerebellum vermis lobule V morphology J:199842
abnormal cerebellum vermis lobule VII morphology J:199842
abnormal cerebellum vermis lobule X morphology J:199842
abnormal hippocampus granule cell layer J:199842
abnormal neuronal precursor proliferation J:199842
abnormal Purkinje cell dendrite morphology J:199842
abnormal Purkinje cell morphology J:199842
cerebellum hypoplasia J:199842
decreased body size J:199842
decreased body weight J:199842
decreased brain weight J:199842
decreased Purkinje cell number J:199842
impaired balance J:199842
impaired coordination J:199842
impaired neuron differentiation J:199842
increased aggression J:199842
postnatal lethality, incomplete penetrance J:199842
premature death J:199842
Gt(ROSA)26Sortm11(CAG-Braf*/ERT2)Rkuhn/Gt(ROSA)26Sortm11(CAG-Braf*/ERT2)Rkuhn
involves: 129S6/SvEvTac * C57BL/6J
no abnormal phenotype detected J:196873

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/18/2018
MGI 6.12
The Jackson Laboratory